News | February 09, 2011

Court Says CoreValve Infringes Patent, to Pay $74 Million

February 9, 2011 – The U.S. District Court for the District of Delaware reaffirmed an April 2010 federal jury decision that determined Medtronic CoreValve LLC willfully infringed Edwards Lifesciences' U.S. Andersen transcatheter heart valve patent and awarded Edwards $74 million in damages.

The court also ruled that Edwards is entitled to recover additional damages due to continued infringing sales from the date of the trial through the life of the patent, plus interest.

In the same ruling, the court denied Edwards' motions for increased damages and a permanent injunction relating to Medtronic CoreValve's willful infringement. Edwards plans to appeal these rulings.

Edwards claims the CoreValve transcatheter aortic heart valves infringes its patents use in its Sapien transcatheter aortic heart valve. The companies are also involved in litigation over the same issue in European courts. Courts in the United Kingdom and German both said the CoreValve did not infringe the patent.

Both valves are currently in FDA pivotal trials seeking FDA clearance. Both valves are already cleared for use in Europe.

For more information: www.edwards.com

Related Content

Mick Jagger Recovering After TAVR Procedure
News | Heart Valve Technology | April 08, 2019 | Jeff Zagoudis, Associate Editor
Rolling Stones frontman Mick Jagger is reportedly recovering after undergoing a transcatheter aortic valve valve...
 Evolut Low Risk Trial compared the minimally invasive Evolut transcatheter aortic valve replacement (TAVR) system to the gold standard of open-heart surgery in characteristically younger, healthier aortic stenosis patients. The randomized trial, which met its primary non-inferiority endpoint of all-cause mortality or disabling stroke at two years compared to surgery (5.3 vs. 6.7 percent; posterior probability of non-inferiority >0.999), was presented at the American College of Cardiology (ACC) 2019 meeting
News | Heart Valve Technology | April 03, 2019
April 3, 2019 – The ACC.19 late-breaking landmark Evolut Low Risk Trial compared the minimally invasive Evolut transc
TAVR Outperforms Surgery in Younger, Low-Risk Aortic Stenosis Patients
News | Heart Valve Technology | March 22, 2019
Among patients with severe symptomatic aortic stenosis at low surgical risk, transcatheter aortic valve replacement (...
ACC Launches Transcatheter Valve Certification
News | Heart Valve Technology | March 14, 2019
March 14, 2019 — Beginning in mid-2019, hospitals performing...
FDA Approves MitraClip for Use in Heart Failure Patients With Functional Mitral Regurgitation
Feature | Heart Valve Technology | March 14, 2019 | Jeff Zagoudis, Associate Editor
March 14, 2019 — The U.S.
Scientists Discover New Type of Immune Cells Essential for Forming Heart Valves

Microscopic images of a normal heart valve in a mouse, left, and a heart valve grown in a lab with heart-derived macrophages blocked, right. Without those macrophages, the valves are thick and deformed. Image courtesy of Developmental Cell/UCLA Broad Stem Cell Research Center.

News | Heart Valve Technology | March 06, 2019
UCLA researchers have identified for the first time the origin of an immune cell that plays a critical role in the...
Global Market for Transcatheter Treatments to Double in Next Five Years
News | Heart Valve Technology | March 01, 2019
When it comes to treatment options for a damaged heart valve, nothing is getting more attention than transcatheter...
Overlay Init